Additional supporting information may be found in the online version of this article at the publisher's website.

jcph288-jcph288-sm-0001-SuppData-S1.docx50KSupplementary Figure Legends and References

Figure S1. Relationships between demographic factors on rivaroxaban pharmacokinetics in patients with non-valvular atrial fibrillation, based on individual post hoc estimates from the current pharmacokinetic model.1 The effects of serum creatinine (SCr) and age on rivaroxaban clearance are shown in (A) and (B), respectively; the effects of lean body mass (LBM) and age on rivaroxaban volume of distribution (V/F) are shown in (C) and (D), respectively. Filled circles represent observed values; straight lines represent trend lines (evaluated using LOWESS).


Figure S2. Box-whisker plots showing estimated levels of rivaroxaban exposure in patients with normal (20 mg) and moderately impaired renal function (CrCl 30–49 mL/min; 15 mg). Shown are plots for Cmax (A) and AUC0–24 (B). Top and bottom of the shaded box correspond to the upper (75%) and lower (25%) percentiles, respectively. The middle white band represents the median; whiskers correspond to the lowest and highest data points within 1.5× interquartile range, calculated from the center of the data. Points beyond this range are possible outliers, indicated by horizontal lines. AUC0–24, area under the concentration versus time curve from 0 to 24 hours; Cmax, maximum plasma concentration; CrCl, creatinine clearance.


Table S1. Rivaroxaban Exposure Individual Parameter Estimates at Steady State: Cmax and AUC0­24 hours

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.